MADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.